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Abstract
Phosphoinositides are essential signaling molecules linked to a diverse array of cellular processes in
eukaryotic cells. The metabolic interconversions of these phospholipids are subject to exquisite
spatial and temporal regulation executed by arrays of phosphatidylinositol (PtdIns) and
phosphoinositide-metabolizing enzymes. These include PtdIns- and phosphoinositide-kinases that
drive phosphoinositide synthesis, and phospholipases and phosphatases that regulate
phosphoinositide degradation. In the past decade, phosphoinositide phosphatases have emerged as
topics of particular interest. This interest is driven by the recent appreciation that these enzymes
represent primary mechanisms for phosphoinositide degradation, and because of their ever-
increasing connections with human diseases. Herein, we review the biochemical properties of six
major phosphoinositide phosphatases, the functional involvements of these enzymes in regulating
phosphoinositide metabolism, the pathologies that arise from functional derangements of individual
phosphatases, and recent ideas concerning the involvements of phosphoinositide phosphatases in
membrane traffic control.
Introduction
Phosphoinositides are phosphorylated derivatives of PtdIns (Fig. 1), and these lipid species
represent quantitatively minor components of cell membranes. In eukaryotic cells, PtdIns
generally constitutes less than 10% of the total cellular phospholipid with Phosphoinositides
usually comprise only several percent of total cellular inositol lipids (Rameh et al.,
1997;Fruman et al., 1998;Martin, 1998;Di Paolo and De Camilli, 2006). However, in spite of
their low abundance, phosphoinositides regulate a host of fundamental cellular processes.
These include signal transduction, intracellular membrane trafficking, cytoskeleton
remodeling, nuclear events, control of cell growth and survival, etc. This functional diversity
of function in part reflects the molecular diversity of these compounds. Mammalian cells
produce seven chemically distinct, but interconvertible, phosphoinositide species:
phosphatidylinositol 3-phosphate (PtdIns-3-P), PtdIns-4-P, PtdIns-5-P, phosphatidylinositol
3,5-bisphosphate (PtdIns-3,5-P2), PtdIns-4,5-P2, PtdIns-3,4-P2, and
phosphatidylinositol-3,4,5-trisphosphate (PtdIns-3,4,5-P3) (Fig. 1). Phosphoinositides
phosphorylated at the 3-OH position are not substrates for phospholipases C, so these
phosphoinositides hold intrinsic signaling functions whose execution is not mediated through
the action of derivative second messengers. It is through the action of phosphatases that 3-OH
phosphoinositides are degraded.
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Yeast produce five phosphoinositide species (Fig. 2), and lack the capacity to generate the
PtdIns-3,4-P2 and PtdIns-3,4,5-P3 species produced by mammals and other higher eukaryotes
(Fig. 3). The 3-OH and 4-OH PtdIns-monophosphate species represent the major
phosphoinositides in yeast, each constituting ca 1.5% of total inositol glycerophospholipid in
this organism (ca. 0.3% of total glycerophospholipid). PtdIns-4,5-P2 is present at
approximately half the mass of PtdIns-3-P or PtdIns-4-P. Basal PtdIns-3,5-P2 levels are
vanishingly low, essentially at the level of detection, until yeast are subject to stress –
particularly hyperosmotic stress (Dove et al., 1997). Upon such challenge, PtdIns-3,5-P2 levels
rise rapidly. The 4-OH phosphoinositides are all essential in yeast as evidenced by
demonstrations that functional ablation of either one of the two major PtdIns 4-OH kinases
(Pik1 and Stt4), or of the single PtdIns-4-P 5-OH kinase (Mss4), represent lethal events.
Although 3-OH phosphoinositides play important homeostatic functions in yeast, these are
essential for cell viability only under stress conditions (Schu et al., 1993;Fruman et al.,
1998;Martin, 1998).
Of the total inositol lipid content in mammalian cells, approximately 5% is invested in PtdIns-4-
P and PtdIns-4,5-P2, respectively – i.e. 0.5% of total cellular phospholipid in each case (Rameh
and Cantley, 1999). These two 4-OH phosphorylated phosphoinositides represent by far the
major phosphoinositide species in mammalian cells, constituting 90% of total cellular
phosphoinositides (Roth, 2004; Di Paolo and De Camilli, 2006). By comparison, less than
0.25% of the total inositol phospholipid is phosphorylated on the D-3 position -- PtdIns-3-P
represents oνλν σoµε 0.04% of total membrane phospholipid (Fruman et al., 1998; Martin,
1998; Whisstock et al., 2002; Roth, 2004; Waselle et al., 2005; Di Paolo and De Camilli,
2006).
The chemically distinct phosphoinositide species each execute unique functions in cells, and
the mono-phosphorylated phosphoinositides are not simple intermediates in production of the
higher poly-phosphorylated species. Translation of chemical diversity to functional diversity
is in part determined by preferred interface of individual phosphoinositide species with
regulatory effector proteins that harbor phosphoinositide - binding domains. Examples include
the pleckstrin homology (PH) domains, phox homology (PX) domains, epsin N-terminal
homology (ENTH) domains, band 4.1/ezrin/radixin/moesin (FERM) and Fab1p/YOTB/
Vac1p/EEA1 (FYVE) domains and lysine–arginine patches (Di Paolo and De Camilli, 2006;
Lemmon, 2008).
All phosphoinositides are restricted to the cytosolic leaflets of intracellular membranes, and
these are not homogeneously distributed in the membranes that contain them (Roth, 2004).
Moreover, the representation of individual phosphoinositide species varies between subcellular
compartments and contributes to establishment and/or maintenance of organelle identity. For
example, PtdIns-3-P is enriched on endocytic membranes, PtdIns-4-P on trans-Golgi (TGN)
membranes, and PtdIns-4,5-P2 is localized primarily on the plasma membrane -- although
Golgi pools are detected. PtdIns-3,5-P2 is most abundant in multivesicular bodies (MVBs) and
late endosomes, on the yeast vacuole, and on mammalian lysosomes (Levine and Munro,
2002; De Matteis and Godi, 2004a; De Matteis and Godi, 2004b; Di Paolo and De Camilli,
2006). PtdIns-3,4,5-P3 is produced almost exclusively on the inner leaflet of the plasma
membrane, although this most highly modified phosphoinositide might also accumulate on
membranes of intracellular organelles and in the nuclear matrix following growth factor
receptor activation (Ellson et al., 2001; Shisheva, 2001; Lee et al., 2002; van Rheenen and
Jalink, 2002; Watt et al., 2002; Waselle et al., 2005).
Steady-state phosphoinositide distribution is the manifestation of a highly dynamic program
of production and turnover executed by the enzymes that regulate phosphoinositide synthesis,
interconversion, and degradation. Under basal conditions, phosphoinositide metabolism is
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tightly regulated by a set of specific kinases that are responsible for synthesis of
phosphoinositides, and phosphatases that temporally and spatially catalyze phosphoinositide
dephosphorylation. The yeast and mammalian phosphoinositide metabolic schemes are
detailed in Fig. 2 and Fig. 3, respectively. In addition, under stimulated conditions,
phospholipases C hydrolyze individual phosphoinositide species (excepting those
phosphorylated on the D3 position) with the consequence of that a variety of soluble inositol
phosphates are produced – each of which apparently manifest potent second messenger
activities (Singer et al., 1997;Liscovitch et al., 2000;Rebecchi and Pentyala, 2000;Strahl and
Thorner, 2007;Majerus et al., 1999).
The anabolic arm of phosphoinositide metabolism is governed by lipid kinases that transfer
the γ-phosphate of ATP to the 3-OH, 4-OH or 5-OH position of the inositol ring. PtdIns kinases
are conserved enzymes found throughout the Eukaryota, and these enzymes are classified into
three major subgroups based on their positional specificities: PtdIns 3-OH kinases (PI3Ks),
PtdIns 4-OH kinases (PI4Ks), and phosphoinositide-kinases (PIPKs) (Loijens et al., 1996;
Zvelebil et al., 1996; Domin and Waterfield, 1997). The PI3Ks constitute a large family of
enzymes responsible for production of PtdIns-3-P, PtdIns-3,4-P2 and PtdIns-3,4,5-P3 (Fig. 2
and fig 3). PI4Ks and PtdIns 5-OH kinase (PI5K) convert PtdIns to PtdIns-4-P or PtdIns-5-P,
respectively. We do note, however that while PI5K activity has been demonstrated in vitro,
there is no available evidence to indicate that PtdIns-5-P is generated from PtdIns by such a
reaction in vivo. Some mammalian enzymes also catalyze the higher order phosphorylation of
PtdIns-5-P or PtdIns-4-P to PtdIns-4,5-P2 (Fig. 3). Unlike most of the cognate mammalian
PtdIns- and phosphoinositide-kinases, the yeast enzymes exhibit exquisite substrate
specificities -- each kinase only phosphorylates a single inositol-phospholipid substrate. Yeast
express one PI3K (Vps34), three PI4Ks (Lsb6, Pik1, and Stt4), one PtdIns-4-P 5-OH kinase
(Mss4), and one PtdIns-3-P 5-OH kinase (Fab1) (Fig. 2) (Flanagan et al., 1993; Schu et al.,
1993; Yoshida et al., 1994a; Yoshida et al., 1994b; Yamamoto et al., 1995; Madania et al.,
1999; Han et al., 2002; Strahl and Thorner, 2007). Of these enzymes, all but one executes
unique biological functions linked to their respective lipid kinase activities. Lsb6 remains
functionally enigmatic.
Phosphoinositide phosphatases: classification and catalytic mechanisms
Phospholipase-independent mechanisms of phosphoinositide degradation are executed by
dephosphorylation of phosphoinositides at the D-3, D-4 and/or D-5 positions of the inositol
ring (Fig. 1), and the responsible phosphoinositide phosphatases are highly conserved
throughout the eukaryotic kingdom. Unlike the case of PtdIns- and phosphoinositide-kinases,
some yeast phosphoinositide phosphatases are promiscuous enzymes with regard to substrate
specificity -- individual enzymes often dephosphorylate multiple phosphoinositide species
(Strahl and Thorner, 2007). The seven known yeast phosphoinositide phosphatases are
classified into three different subgroups on the basis of their catalytic domain properties. These
include the SAC-domain phosphatases, the inositol polyphosphate 5-phosphatase domain
enzymes, and the myotubularin ortholog Ymr1 (Fig. 4;Strahl and Thorner, 2007). Mammalian
phosphatases are classified into two superfamilies: the protein tyrosine phosphatase
superfamily, and the inositide polyphosphate phosphatase superfamily.
The phosphoinositide phosphatases of the PTP-superfamily fall into four primary classes. The
phosphoinositide 4-phosphatases fall into types I and II that share 37% primary sequence
identity, and primarily degrade PtdIns-3,4-P2 to PtdIns-3-P (Norris et al., 1997; Nystuen et
al., 2001). The weeble ataxia mouse is deficient in the type 1 enzyme (Nystuen et al., 2001).
PTEN, the famous PtdIns-3,4,5-P3 3-phosphatase, also belongs to the PTP-superfamily. The
Sac1-like phosphoinositide phosphatases fall into two categories – the stand-alone SAC-
domain enzymes that show relaxed positional specificity with regard to phosphoinositide
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substrate, and the dual functional enzymes that exhibit tandem arrangements of SAC-domains
appended to phosphoinositide 5-phosphatase domains (e.g. the synaptojanins). Finally, the
myotubularins constitute an intriguing class of phosphoinositide 3-phosphatases.
Phosphoinositide phosphatases of the PTP superfamily are metal-independent enzymes that
exhibit a signature Cys-X5-Arg-Thr/Ser (CX5RT/S) active site motif which physically cradles
the various chemical steps of the reaction mechanism (Fig. 4A). First, the PO3 moiety from
the phospho-inositol headgroup is accepted by the nucleophilic cysteine residue within the
CX5RT/S motif to generate a phosphocysteine intermediate. The invariant arginine of the
CX5RT/S motif stabilizes the transition-state so that the PO3 moiety is subsequently transferred
to a water molecule. Finally, a conserved aspartic acid from an adjacent structural loop
completes the catalytic cycle by protonating the leaving-group oxygen and reconstituting an
uncharged hydroxy group at the position from which the phosphate moiety was originally
removed (Guan and Dixon, 1991;Fauman and Saper, 1996;Hughes et al., 2000a).
The phosphoinositide 5-phosphatases fall into four categories. The group I enzymes act only
on soluble inositol polyphosphates (Ins-1,4,5-P3 and Ins-1,3,4,5-P4), the group II enzymes (e.g.
OCRL1; discussed at length below) utilize both phosphoinositide RIPT and soluble inositol
phosphate substrates, and the group III enzymes (e.g. SHIP1 and SHIP2; see below) utilize
phosphoinositides as preferred substrates. Finally, the group IV enzymes act exclusively on
PtdIns-3,4,5-P3 and PtdIns-4,5-P2.
The inositol polyphosphate 5-phosphatase exhibit structural folds similar to those of Mg2+-
dependent endonucleases, and all of these enzymes exhibit magnesium-dependent
phosphomonoesterase activities (Mitchell et al., 1996; Blero et al., 2007; Majerus and York,
2009). Bioinformatic approaches, coupled with mutagenesis studies, further indicate the
inositol polyphosphate 5-phosphatases share the same principle catalytic mechanism as the
apurinic/apyrimidinic base excision repair endonucleases (Dlakić, 2000; Whisstock et al.,
2000). The model catalytic mechanism employs a nucleophilic water molecule that is
positioned and activated by an invariant Asp residue – a residue that is itself properly oriented
by H-bonding to the side-chain of a conserved Asn (Fig. 4B). The target 5’-phosphate group
of the inositol headgroup is configured for the nucleophilic attack by an invariant His/Asp pair
and an invariant Asn. A metal ion (Mg2+) stabilizes the transition state of the inversion of
configuration of the phosphate with the result that the PO3 moiety is transfered to water and
the dephosphorylated inositol phospholipid product is released (Fig. 4B). It is not clear whether
the proton donor that stabilizes the inositol leaving group is a water molecule or some other
functional group of the enzyme (Whisstock et al., 2000).
Phosphatases of both the double-displacement class (i.e. members of the PTP superfamily that
displace the inositol leaving group via an active-site nucleophile and phospho-enzyme
intermediate; Fig. 4A), and the class of phosphatases that catalyze direct displacement of the
inositol leaving group via nucleophilic water (i.e. members of the inositol polyphosphate 5-
phosphatase family; Fig. 4B), are truly remarkable enzymes with regard to their catalytic
proficiencies (Lad et al., 2003). Both classes of enzymes enhance reaction rates some 17- to
20-orders of magnitude over spontaneous rates. That is, the reactions catalyzed by phosphatases
at subsecond time scales occur spontaneously with half-times of ca. 1 × 1012 years (Lad et al.,
2003)!
This review is focused on the phosphoinositide phosphatases and their various involvements
in membrane trafficking and cellular homeostasis. Linkage of individual enzymes to
mammalian disease is also discussed. For purposes of clarity, the domain organizations of the
relevant phosphoinositide phosphatases are illustrated in Fig. 5, while the subcellular
distributions of the various phosphoinositide phosphatases are illustrated in Fig. 6.
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The PTEN/MMAC1/ TEP1 (phosphatase and tensin homolog/mutated in multiple advanced
cancers/TGFβ-regulated and epithelial cell–enriched phosphatase) gene was originally
identified as a candidate tumor suppressor gene located on human chromosome 10q23 (Li and
Sun, 1997; Li et al., 1997; Myers et al., 1997; Steck et al., 1997; Ali et al., 1999). PTEN harbors
the CX5RT/S phosphatase catalytic signature and shares primary sequence similarity with
members of the protein tyrosine phosphatase superfamily – a circumstance that prompted the
initial suggestion that PTEN is a protein phosphatase. This hypothesis is not supported by
biochemical characterizations which indicate recombinant PTEN is a poor protein phosphatase
in vitro, irrespective of whether the enzyme is presented with phospho-Ser, phospho-Thr or
phospho-Tyr substrates (Li and Sun, 1997; Li et al., 1997; Myers et al., 1997). Rather, PTEN
exhibits a significant phosphoinositide phosphatase activity that targets the D-3 phosphate of
PtdIns-3-P, PtdIns-3,4-P2 and PtdIns-3,4,5-P3 substrates. PtdIns-3,4,5-P3 is the preferred
substrate in vitro and is a primary PTEN substrate in vivo (Myers et al., 1997; Maehama and
Dixon, 1998). The unimpressive activity of PTEN towards phosphopeptide substrates, while
consistent with the idea it is a primarily lipid phosphatase, does not exclude the possibility that
PTEN is also a protein phosphatase -- but one with an exquisite substrate specificity. This issue
is further discussed below.
PTEN consists of a ca. 200 residue N-terminal phosphatase domain required for catalytic
activity (Fig 6; Lee et al., 1999;Maehama et al., 2001). The PTEN CX5R(S/T) motif resides
within an enlarged active site that surrounds the catalytic signature with three basic residues,
and these residues are critical for PTEN lipid phosphatase activity (Maehama et al., 2001).
This structural arrangement endows PTEN with its preference for highly acidic phospholipid
substrates such as PtdIns-3,4,5-P3. Interestingly, PTEN protein- and phosphoinositide-
phosphatase activities can be uncoupled. The G129E missense mutation alters the
phosphoinositide binding pocket and selectively eliminates PTEN phosphoinositide-
phosphatase activity in vitro (Myers et al., 1998).
That PtdIns-3,4,5-P3 is a PTEN substrate is of great interest as this phosphoinositide is the
terminal lipid product of forward PI3K signaling and, as such, represents a potent promoter of
cell growth and survival. PtdIns-3,4,5-P3 exerts its proliferative effects by activating the Ser/
Thr protein kinase PDK1. In turn, PDK1 activates the proto-oncogenic protein kinase Akt
which contains a PtdIns-3,4,5-P3 – responsive PH domain (Coffer et al., 1998; Fruman et al.,
1998; Rameh and Cantley, 1999; Downes et al., 2007). That PTEN is truly involved in
PtdIns-3,4,5-P3–mediated activation of Akt is supported by demonstrations that both cellular
PtdIns-3,4,5-P3 and activated Akt levels are constitutively elevated in PTEN-deficient mouse
embryonic fibroblasts (Sun et al., 1999; Stambolic et al., 2000). Reciprocally, PTEN
overexpression downregulates Akt activity and depresses cellular PtdIns-3,4,5-P3 levels (Di
Cristofano et al., 1998; Cantley and Neel, 1999; Di Cristofano et al., 1999). These data identify
PTEN as an antagonist of proliferative signaling – i.e. a tumour suppressor. Consistent with a
homeostatic function, PTEN is ubiquitously expressed throughout early embryogenesis in
mammals (Di Cristofano et al., 1998; Sun et al., 1999; Suzuki et al., 2008).
It is difficult to overstate the enormous significance of the PtdIns-3,4,5-P3/AKT/PTEN
regulatory circuit from the standpoint of human disease. Over the past two decades, PTEN has
blossomed into one of the featured molecules in cancer biology. Hundreds of published reports
focus on PTEN structure, function, and mutations in the context of various human diseases.
After p53, PTEN is the most commonly mutated gene in human cancer, and the most deleted/
mutated phosphatase in human sporadic and hereditary cancer syndromes such as Cowden
disease, glioblastoma, prostate and endometrial cancers, Bannayan – Zonana syndrome, and
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Lhermitte – Duclos disease, among others (Liaw et al., 1997; Nelen et al., 1997; Stiles, et
al., 2004; Suzuki et al., 2008). As some of these syndromes are sensitive to inhibitors of the
Target-of Rapamycin (TOR) pathway, and are at least superficially phenocopied by
overexpression of downstream components of the TOR pathway, PTEN deficiencies evoke
their homeostatic defects in part via deranged TOR signaling (Podsypanina et al., 2001; Atkins
et al., 2004; Wendel et al., 2004; Chan et al., 2005). Consistent with a role for PTEN as critical
regulator of cellular homeostasis, PTEN nullizygosity in mice results in early embryonic
lethality, and heterozygosity results in elevated incidence of various cancers and autoimmune
diseases (reviewed in Stiles et al., 2004; Suzuki et al., 2008). PTEN and p53 also show a
functional connection. PTEN transcriptional expression is activated by p53, and this circuit
contributes to initiation of p53-dependent apoptotic responses and p53-dependent senescence
programs as consequences of downregulated PtdIns 3-OH kinase signaling (Jin and Levine,
2001; Stambolic et al., 2001; Feng et al., 2005).
The dual activities of PTEN as a protein tyrosine- and a phosphoinositide-phosphatase pose
the interesting question of which activity is the most directly relevant for PTEN action as
tumour suppressor. This issue was initially brought to the fore by reports that PTEN protein
tyrosine phosphatase activity is directed at key signaling proteins such as focal adhesion kinase
and the adaptor protein Shc (Gu et al., 1998; Gu et al., 1999; Yamada and Araki, 2001).
However, the available data fall most convincingly in favor of the phosphoinositide
phosphatase activity representing the key anti-proliferative activity of PTEN. The
PTENG129E separation of function allele does not compromise PTEN tumour suppressor
activity (Myers et al., 1998), and studies in D. melanogaster demonstrate that PTEN-deficient
flies are rescued by mutation of the PtdIns-3,4,5-P3-specific PH domain of Akt (Stocker et
al., 2002).
Although PTEN protein tyrosine phosphatase activity does not play a major role in tumour
suppressor function, several lines of evidence suggest the PTEN tyrosine protein phosphatase
activity is of relevance in specific physiological contexts (Vasquez et al., 2000; Raftopolou et
al., 2004; Vogelmann et al., 2005; Leslie et al., 2007; Leslie et al.,2009). Although β-catenin
is proposed as a direct target for PTEN protein tyrosine phosphatase activity (Vogelmann et
al., 2005), the best data suggest PTEN catalyzes an auto-dephosphorylation reaction in order
to promote the conformational transitions required for the priming of PTEN C-terminal
domains for physiologically important protein binding functions (Vasquez et al., 2000;
Vasquez et al., 2001; Raftopolou et al., 2004; Leslie et al., 2007; Leslie et al., 2009). A thorough
test of these hypotheses will be greatly facilitated by PTEN mutations that selectively inactivate
protein tyrosine phosphatase activity without compromising lipid phosphatase activity.
The central role for PTEN is attenuating proliferative signaling demands the enzyme be tightly
regulated – both spatially and temporally. The domain structure of the phosphatase suggests
this is indeed the case. A lipid-binding C2 domain is configured C-terminal to the phosphatase
domain, and PTEN exhibits a PDZ-binding motif at its C-terminus (Fig 6). The latter motif is
proposed to regulate PTEN subcellular localization via interactions with PDZ domain-
containing scaffolding proteins typically associated with the sub-plasma membrane
cytoskeleton -- such as the membrane associated guanylate kinase-like protein MAG1 (Lee et
al., 1999;Wu et al., 2000;Vazquez et al., 2001). With regard to localization, PTEN exhibits a
rather broad distribution across intracellular compartments; having been reported to localize
to the plasma membrane, Golgi complex and nucleus (Fig. 6;Myers et al., 1998;Lee et al.,
1999;De Matteis and Godi, 2004a). In this regard, while PTEN is evolutionarily conserved
throughout the eukaryotic kingdom (with homologs in yeast, Drosophila, C. elegans and
mammals), the domain arrangements vary among the various forms. For instance, the C2
domain is absent from PTEN enzymes of simpler eukaryotes, and the Drosophila and C.
elegans PTEN proteins exhibit longer C-terminal tails than does human PTEN. The PDZ-
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binding domain is also missing from some Drosophila PTEN isoforms (Goberdhan et al.,
1999;Lee et al., 1999;Maehama et al., 2001;Goberdhan and Wilson, 2003).
In addition to the two lipid-binding signatures recognized by sequence homologies, PTEN also
exhibits a conserved N-terminal polybasic motif. This motif is interrupted by a K13E missense
substitution recovered from a sporadic human glioblastoma -- the consequences of which
include diminished activation of PTEN phosphatase activity by PtdIns-4,5-P2 and non-
functionality of the mutant protein in a variety of in vivo contexts (Walker et al., 2004). Because
the substitution does not compromise PTENK13E activity against soluble Ins-1,3,4,5-P4, i.e.
the soluble cognate of the PtdIns-3,4,5-P3 headgroup, or PtdIns-3,4,5-P3 incorporated into
neutral phosphatidylcholine liposomes, the data suggest this polybasic motif binds non-
substrate acidic phospholipids to orient PTEN onto membrane surfaces for optimal activity
against its lipid substrates. In support of this conclusion, myristoylation of the PTENK13E N-
terminus restores protein function (Walker et al., 2004). Further evidence for the functional
importance of the PTEN N-terminus is provided by the S10N missense substitution identified
from a non-Hodgkins malignant lymphoma (Bonneau and Longy, 2000). PTENS10N exhibits
respectable catalytic activity in vitro, suggesting the mutant enzyme is defective in some
regulatory aspect (Han et al., 2000). In that regard, the S10N substitution lies within the basic
cluster interrupted by the K13E substitution.
PTEN activity is also regulated by interesting sets of binding partners. Recently, it was reported
that transport of PTEN to the neuronal plasma membrane, presumably the primary site at which
it encounters its PtdIns-3,4,5-P3 substrate, is controlled by the actin-based motor protein
myosin Va (van Diepen et al., 2009). A combination of co-immunoprecipitation and Förster
resonance energy transfer experiments suggest a direct interaction between PTEN and myosin
Va, and indicate the interaction is promoted by phosphorylation of PTEN by casein kinase 2
and glycogen synthase kinase 3. Myosin Va deficiencies, as well as PTEN defects, lead to
increased size of neuronal cells in a manner that is dependent on PtdIns 3-OK kinase and mTOR
signaling (Mercer et al., 1991; van Diepen et al., 2009). Following a similar theme, the
Drosophila PTEN associates directly with the Par-3 component of the PAR/atypical protein
kinase C complex involved in establishment and maintenance of cell polarity (von Stein et al.,
2005). In fly ovaries and embryos lacking PTEN, the actin cytoskeleton is disorganized.
Failures in asymmetric distribution of specific mRNAs, in posterior movements and
synchronous nuclear divisions, and in cellularization, are also observed (von Stein et al.,
2005).
Finally, regulation of PTEN activity by a binding partner has been documented. Peroxiredoxin
1 (Prdx1), a low efficiency peroxidase scavenges reactive oxygen species binds PTEN through
its C2 domain (Cao et al., 2009). The Prdx1-PTEN interaction prevents inactivation of PTEN
by reactive oxygen species. This finding, when coupled with the rather unimpressive catalytic
efficiency of Prdx1, suggests a privileged relationship between PTEN and Prdx1. Reductions
in Prdx1 activity result in enhanced basal and peroxide- and growth factor-induced Akt
signaling (Cao et al., 2009).
PTEN2, TPTE and TPIP
Humans express several other proteins with primary sequence similarity to PTEN. These
include PTEN2, the Transmembrane Phosphatase with TEnsin homology (TPTE), and the
TPTE and PTEN homologous Inositol lipid Phosphatase (TPIP). Both humans and mice are
reported to express PTEN2 proteins (Wu et al., 2001). Murine PTEN2 is a testes-specific
protein expressed primarily in secondary spermatocytes and early spermatids – an expression
pattern suggestive of a role for this protein in the terminal stages of spermatocyte
differentiation. The protein localizes to the medial/trans-compartments of the Golgi complex,
and is reported to have detectable phosphoinositide 3-phosphatase activity with a substrate
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specificity resembling that described for PTEN (Wu et al., 2001). A signature feature of PTEN2
that distinguishes it from PTEN is presence of an extended N-terminal domain that contains
four putative transmembrane domains. This extension is necessary and sufficient for
localization of murine PTEN2 to Golgi membranes, and these transmembrane domains have
been speculated (with no real evidence in support) as having the potential to form an ion channel
(Wu et al., 2001).
Human TPTE and TPIP proteins were independently identified by several groups, and these
species also harbor 2 or 3 putative transmembrane domains in their N-termini (Chen et al.,
1999; Walker et al., 2001). The mouse contains only a single TPTE gene from which various
spliceoforms are generated, while humans express perhaps as many as three functional TPTE
structural genes (Guipponi et al., 2001). Nothing is known whether these TPTE gene products
are functionally distinct in any significant way. With regard to human TPTE, of which two
isoforms (TPTEα and TPTEβ) have been characterized in some detail, Walker et al. (2001)
find these proteins to be devoid of phosphoinositide phosphatase activities and to localize to
the plasma membrane. The inactivity of these proteins as phosphoinositide phosphatases is
consistent with the presence of missense substitutions that introduce acidic residues in the
active site pocket, substitutions whose PTEN cognates compromise the phosphoinositide-3-
phosphatase activities of this enzyme (Walker et al., 2001). Some confusion has arisen after
the assignment of murine PTEN2 by Wu et al. (2001) as the orthologue of the human
TPTEα described by Chen et al. (1999). The enzymatic and localization properties of human
TPTEα reported by Walker et al. (2001) diverge significantly from those reported for murine
PTEN2 by Wu et al. (2001). It is argued on the basis of these differences that murine PTEN2
and human TPTEα proteins are not orthologous (Walker et al., 2001).
TPIPs are characterized as novel PTEN homologs that are expressed as two predominant
isoforms designated TPIPα and TPIPβ (Chen et al., 1999; Walker et al., 2001). TPIPα is
homologous to PTEN within the phosphatase and C2 domains (Fig. 6), but lacks the C-terminal
tail which harbors the PDZ-binding domain and phosphorylation sites proposed to regulate
PTEN stability and activity (Maehama et al., 2001; Simpson and Parsons, 2001; Walker et
al., 2001). This isoform exhibits clearly measurable phosphoinositide 3-phosphatase activity
(but little of any Ins-1,3,4,5-P4) phosphatase activity), is expressed most highly in testis, brain
and stomach, exhibits two or three potential trans-membrane domains in its N-terminal region,
and localizes to the ER (Walker et al., 2001). By contrast, TPIPβ is expressed in a testis-specfic
manner and is truncated at both the N- and C-termini relative to TPIPα. Thus, TPIPβ lacks both
the putative trans-membrane domain region and the C2-domain and, consequently, does not
bind stably to membranes. Moreover, recombinant TPIPβ presents no measurable
phosphoinositide phosphatase activity (Walker et al., 2001). The collective data indicate the
minimal phosphatase requires both the catalytic- and C2-domains to generate a functional
module. Although, TPIPα is a phosphoinositide 3-phosphatase, it does not appear to couple
physiologically to the PTEN-sensitive PtdIns-3,4,5-P3 pools involved in activation of PDK1
and Akt (Walker et al., 2001).
The Myotubularins
Myotubularin (MTM1), the founding member of the myotubularin family, was discovered by
isolation of a gene mutated in X-linked centromyotubular myopathy (Laporte et al., 1996).
MTM1 is a CX5RT/S motif protein that exhibits potent PtdIns-3-P phosphatase activity
(Blondeau et al., 2000; Taylor et al., 2000). The large MTM-related (MTMR) protein family
is highly conserved from yeast to man. Humans express 14 MTMR family members and,
consistent with how these proteins were discovered, interest in MTMR proteins is stoked by
their disease relevance. Mutations in several genes of this family are root causes of myotubular
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myopathy and Charcot-Marie-Tooth peripheral neuropathies (Clague and Lorenzo, 2005;
Robinson and Dixon, 2006).
The myotubularins are recognized as key components of the homeostatic strategy for regulation
of PtdIns 3-phosphate and PtdIns-3,5-P2 levels in eukaryotic cells (Maehama et al., 2001;
Tronchere et al., 2003; Tronchere et al., 2004). Human MTM1, and MTMR1,2,3,4,6,7 are
phosphoinositide 3-phosphate phosphatases with substrate preferences restricted to PtdIns-3-
P and PtdIns-3,5-P2 (Tronchere et al., 2003; Tronchere et al., 2004). Curiously, nearly half of
the metazoan MTM family members contain naturally-occurring missense substitutions that
involve the Cys and Arg residues of the canonical CX5R(S/T) motif, thereby disqualifying
these enigmatic proteins as catalytically-active phosphatases (Wishart et al., 2001; Laporte et
al., 2003; Taylor and Dixon, 2003; Clague and Lorenzo, 2005; Robinson and Dixon, 2006).
In at least several cases, the naturally inactive MTMs -- by virtue of their heterodimerization
with catalytically competent members of the MTM family -- play important roles in regulation
of mammalian phosphoinositide homeostasis (Clague and Lorenzo, 2005; Robinson and
Dixon, 2006). Perhaps the inactive subunits are critical for appropriate presentation of the
substrate phosphoinositide to the catalytically active subunit in cellular contexts. This
interesting arrangement does not hold for all myotubularins, however. S. cerevisiae expresses
a single active MTM1 homolog (yeast myotubularin-related 1; Ymr1), and the yeast genome
does not display catalytically-inactive members of this family (Taylor et al., 2000; De Matteis
and Godi, 2004a; Robinson and Dixon, 2006).
Metazoan MTMRs are categorized into six subclasses, three of which define groups of naturally
inactive phosphatases (Wishart et al., 2001; Laporte et al., 2003; Taylor and Dixon, 2003). The
common MTM domain structures include a PHGRAM (pleckstrin homology
glucosyltransferases, Rablike GTPase activators and myotubularins) module and a ca. 370
residue central PTP domain (Fig. 5; Begley et al., 2003). Coiled-coil regions that presumably
organize interactions with other proteins reside C-terminal to the phosphatase domain in most
MTMR proteins. The MTMR3/4 and MTMR5/13 subclasses contain additional conserved
modules, including FYVE, DENN and PH domains (Begley et al., 2003; Robinson and Dixon,
2006). Localization studies identify MTMs as peripheral membrane proteins of endosomal
compartments (Zhao et al., 2001; Laporte et al., 2002; Mochizuki and Majerus, 2003) – i.e.
profiles consistent with involvements of these proteins in control of the PtdIns-3-P and
PtdIns-3,5-P2 signaling that is intimately linked to protein trafficking through the endosomal
system (Fig 6). PtdIns-3-P and PtdIns-3,5-P2 are present on endosomal compartments --
PtdIns-3-P predominates on early endosomes, and PtdIns-3,5-P2 on late endocytic organelle
membranes. Insufficiencies in PtdIns-3-P and PtdIns-3,5-P2 phosphatase activity compromise
turnover of these endosomal phosphoinositides, derange membrane trafficking through this
system, and it is this set of basic cellular malfunctions that manifests itself most strikingly in
pathologies of post-mitotic cells (e.g. neurons).
SAC-Domain Phosphoinositide Phosphatases
The Sac1-like phosphoinositide phosphatases are characterized by a domain arrangement for
which the yeast Sac1 protein serves as prototype (Cleves et al., 1989; Chung et al., 1997; Guo
et al., 1999). SAC-domain proteins are divided into two subgroups. One group is characterized
by a stand-alone Sac domain. Examples include yeast Sac1 and Fig4, and other proteins
expressed by various species – e.g. the human KIAA0274, KIAA0851 and KIAA0966 proteins.
The second group presents a Sac1-like-phosphatase module configured adjacent to a 5-
phosphatase domain. Examples include mammalian synaptojanins 1 and 2, and the cognate
yeast phosphatases Inp51/Sjl1, Inp52/Sjl2, and Inp53/Sjl3 (Srinivasan et al., 1997; Stolz et
al., 1998; Hughes et al., 2000a).
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Yeast and Mammalian Sac1 Phosphatases
The founding member of the SAC-domain phosphoinositide phosphatase family was identified
in yeast by two independent genetic screens searching for novel actin-regulatory proteins and
novel regulators of membrane trafficking through the yeast trans-Golgi/endosomal networks,
respectively (Cleves et al., 1989; Novick et al., 1989; Whitters et al., 1993). While it was
explicitly postulated that Sac1 (suppressor of actin) is an antagonist of 4-phosphoinositide
signaling, and that it is this function that accounts for the effects of sac1 mutations on actin
organization and membrane trafficking (Cleves et al., 1991), the demonstration that Sac1 is a
phosphoinositide phosphatase came only eight years later (Guo et al., 1999). Sac1 is a type II
integral membrane protein that disposes the N-terminal and C-terminal Sac1 domains to the
cytosol (Fig. 5), it localizes to endoplasmic reticulum (ER) and Golgi membranes in yeast and
in animal cells (Fig. 6), and the protein is anchored to membranes by two C-terminal
transmembrane domains (Cleves et al., 1989; Whitters et al., 1993; Nemoto et al., 2000; Liu
et al., 2008; Mayinger, 2009). Sac1 and its orthologs are the only integral membrane proteins
of the SAC1-domain family of phosphatases, and this property is essential for optimal catalytic
activity in cells (Rivas et al., 1999; Foti et al., 2001). Genetic ablation of Sac1 function in yeast
is not a lethal event, and a chromosomal sac1Δ allele recapitulates the genetic interactions
exhibited by sac1 alleles recovered from the actin- and TGN-directed genetic screens (Cleves
et al., 1989). Thus, the two genetic screens through which Sac1 was identified uncovered
genuine loss-of-function mutations. Other phenotypes include cold-sensitivity for growth, cell
wall abnormalities, and assorted ER-associated defects (Cleves et al., 1989; Novick et al.,
1989; Kochendörfer et al., 1999).
Biochemical and in vivo inositol-labeling experiments demonstrate yeast Sac1 and its
mammalian homologs are promiscuous phosphoinositide phosphatases that show little
positional specificity with regard to phosphoinositide substrate -- PtdIns-3-P, PtdIns-4-P,
PtdIns-5-P, and PtdIns-3,5-P2 are all acceptable substrates (Guo et al., 1999). The exceptions
to the rule are PtdIns-3,4-P2 and PtdIns-4,5-P2. Thus, Sac1 domains cannot degrade poly-
phosphoinositides with vicinal phosphates. In yeast, it is clear the major in vivo substrate for
Sac1 is PtdIns-4-P; a conclusion rigorously established by headgroup chemical analysis of the
predominant phosphoinositide species that accumulates in Sac1-deficient yeast (Guo et al.,
1999; Rivas et al., 1999). Indeed, genetic ablation of Sac1 activity effects 8- to 10-fold increases
in PtdIns-4-P mass in yeast with little effect on the other phosphoinositides (Guo et al.,
1999; Rivas et al., 1999; Hughes et al., 2000a; Hughes et al., 2000b; Nemoto et al., 2000). The
massive accumulation of PtdIns-4-P is a large part of the mechanism, but not the entire
mechanism, for why Sac1 defects alter membrane trafficking from the yeast TGN (Xie et al.,
1998; Rivas et al., 1999; Li et al., 2002). Thus, the in vitro promiscuity of the enzyme
notwithstanding, Sac1 exhibits impressive substrate specificity in vivo. This substrate
specificity is likely a revealing manifestation of how the enzyme encounters its substrate
phosphoinositides.
The Sac1 substrate specificity is all the more intriguing in that not all PtdIns-4-P pools are
accessed by Sac1. The source of PtdIns-4-P matters as, at least under normal growth conditions,
yeast Sac1 specifically degrades the PtdIns-4-P generated by one of the two essential PtdIns
4-OH kinases in yeast – i.e. the plasma membrane isoform Stt4 – with insignificant access to
the PtdIns-4-P pool generated by the other essential yeast PtdIns 4-OH kinase Pik1 (Nemoto
et al., 2000; Foti et al., 2001; Routt et al., 2005). This intriguing functional relationship is not
well understood given the localization of Stt4 to the plasma membrane and Sac1 residence in
intracellular membrane compartments. Ideas for how to reconcile this apparent physical
paradox are emerging (see below). The effects of Sac1 dysfunction are not limited to PtdIns-4-
P. Larger derangements of lipid metabolism are apparent in Sac1-deficient yeast – particularly
in neutral lipid metabolism (Kearns et al., 1997; Rivas et al., 1999; Foti et al., 2001).
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Sac1 cycles between the ER and Golgi – indicating cells impose regulatory oversight on the
mechanisms by which Sac1 is retained in, and retrieved from, distinct intracellular
compartments. As discussed below, interesting cell biology is associated with such a trafficking
itinerary. Retention of Sac1 in the yeast ER is reported to be mediated by an interaction of the
Sac1 C-terminal tail with Dpm1, the highly abundant ER dolicholphosphate-mannose
synthase. Functional ablation of this interaction disrupts ER localization of the enzyme
(Faulhammer et al., 2005). How yeast Sac1 is recognized as a retrograde cargo in Golgi
membranes is not understood.
A different strategy for Sac1 traffic control is in evidence in mammalian cells. Whereas Sac1
also cycles between the mammalian ER and Golgi, its competence for exit from the ER
compartment requires oligomerization of the enzyme via a leucine-zipper motif – a motif not
present in yeast Sac1 (Blagoveshchenskaya et al., 2008). How the enzyme is retrieved from
Golgi compartments back to the ER is known, however. Mammalian Sac1 presents a C-
terminal KXKXX motif that serves as binding site for the coatomer (COPI) complex, the
presumptive coat for retrograde trafficking vesicles, and is obligately required for retrieval of
the enzyme from the Golgi back to the ER (Fig. 5; Rohde et al., 2003; Liu et al., 2008).
Interaction of Sac1 with the COP1 machinery requires disassembly of the Sac1 oligomers.
Functional integrity of the Sac1/COPI complex also demands that Sac1 be an active
phosphatase, and assembly of this complex is dynamically regulated by cell-growth conditions
(Rohde et al., 2003; Blagoveshchenskaya et al., 2008; Liu et al., 2008). How Sac1 phosphatase
activity regulates this interaction is unclear, but some phosphoinositide species (PtdIns-4-P?)
likely inhibit the interaction – directly or indirectly. Such a mechanism promises a different
paradigm for how phosphoinositides regulate cargo::vesicle coat protein interactions. In the
late secretory and endocytic pathways, phosphoinositides are positive regulators that faciltitate
cargo interactions with coat proteins (De Matteis and Godi, 2004a; Mayinger, 2009). At any
rate, it is abundantly clear that endogenous Sac1 levels (at least in yeast) are saturating -- given
that 20-fold overproduction of Sac1 protein has no effect on cell viability, phosphoinositide
homeostasis, or ER localization of the enzyme (Cleves et al., 1989; Rivas et al., 1999; Liu et
al., 2008).
Unlike the case in yeast, the single mammalian Sac1 isoform executes essential cellular
functions (Liu et al., 2008). Nullizygous embryos exhibit pre-implantation lethality obvious
by the blastocyst stage, and siRNA experiments report a loss of viability upon acute Sac1
depletion in cultured mammalian cells. One obvious intracellular phenotype associated with
Sac1-depletion is a manifest disorganization of cis-, medial-and trans-Golgi compartments in
the absence of obvious morphological derangements of other compartments of the secretory
pathway. The structurally disturbed Golgi membranes show no overt membrane trafficking
defects, however (Liu et al., 2008). Instead, Sac1-depleted cells fail to exit mitosis and present
a high incidence of spindle disorganization highlighted by ectopic and mechanically-active
spindle asters. These deviant spindle asters are marked with γ-tubulin but, as is normally the
case, only two of the asters harbor centrosomal Centrin-2 landmarks. Thus, licensing of
centrosome division is unperturbed in Sac1-deficient cells. The mechanical activity of ectopic
spindle asters, when coupled with the failure of multipolar spindles to efficiently resolve,
promotes catastrophic defects in chromosomal segregation (Liu et al., 2008). Complementation
experiments show Sac1 phosphoinositide phosphatase activity, and recycling from the Golgi
back to the ER, are functional properties required for Sac1 activity in vivo (Liu et al., 2008).
Why is Sac1 ER-localization a conserved and functionally important feature for this
phosphoinositide phosphatase? The ER is not a compartment generally associated with
phosphoinositide signaling. One possibility is Sac1 scavenges ‘wandering’ phosphoinositides
in the ER for the purpose of degrading mislocalized phosphoinositide molecules that would
otherwise confuse phosphoinositide-centric mechanisms for establishing and maintaining
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organelle identity. This model confronts two issues. First, Sac1 is particularly tuned to activity
of the plasma membrane Stt4 (mammalian PtdIns kinase α), yet inactivation of this circuit is
not lethal in yeast nor is the secretory pathway particularly confused regarding organelle
identities in sac1Δ cells that accumulate dramatic amounts of PtdIns-4-P. While Sac1-deficient
mammalian cells do not thrive, these nonetheless traffic proteins quite normally – even though
Golgi structure is deranged (Liu et al., 2008). On balance, it does not seem likely that Sac1
plays dedicated phosphoinositide cleanup duty with the ER as repository for mislocalized
phosphoinositides. It would seem surface dilution of phosphoinositide across a large ER area
would confound such cleanup strategies anyway.
Alternatively, Sac1 may coordinate plasma membrane and ER functions and, by orienting itself
on the ER surface at points of apposition with the plasma membrane (membrane contact sites?),
degrade excess phosphoinositide on the plasma membrane. If that were the simple case, one
would expect significant and specific PtdIns-4-P accumulation in the plasma membrane in
Sac1-deficient cells. Although there is one report to suggest this is the case (Roy and Levine,
2004), other experiments report PtdIns-4-P accumulation in ER-like compartments of Sac1-
deficient yeast cells (Li et al., 2002; Woods et al., 2009). These phosphoinositide localization
data yeast amply demonstrate the reporter-dependence of the visualized phosphoinositide
profile, emphasizing yet again that caution must be exercised in interpreting the results obtained
with such biosensors. The idea that Sac1 is either a component of, or takes advantage of,
membrane contact sites to access specific PtdIns-4-P pools remains an open question. More
expansive discussions of putative membrane contact sites are found in several recent treatments
of this topic (Pichler et al., 2001; Levine and Loewen, 2006; Peretti et al., 2008).
The involvement of mammalian Sac1 in cell cycle progression and mitotic spindle
organization, suggests the simplest possibility may hold the most merit. That is, Sac1 localizes
to the ER because it regulates phosphoinositide-mediated signal transduction from cytosolic
compartments, perhaps even the ER, to the nucleus or nuclear envelope. The nuclear matrix is
an active compartment for phosphoinositide-signaling (Cocco et al., 1987; Divecha et al.,
1991; Irvine and Divecha, 1992; Irvine, 2003; Martelli et al., 2005; Gonzales and Anderson,
2006), and one can imagine a dedicated role for an ER-localized phosphatase in survey of
phosphoinositide status on the nuclear envelope (which is contiguous with the ER). Nuclear
pores are attractive sites for such surveillance. It is around these structures that continuities
occur between the cytosolic membrane leaflet of the ER/nuclear envelope and the leaflet that
faces the nuclear matrix.
Alternatively, Sac1 may regulate nuclear envelope dynamics in specific physiological contexts.
Nuclear envelope assembly and disassembly occurs during the mammalian mitotic cycle, and
the process is also highly regulated in non-somatic cells such as fertilized oocytes (Larijani
and Poccia, 2009). Evidence for a direct role for phosphoinositides in regulating nuclear
envelope assembly is provided by Larijani and colleagues who demonstrated sea urchin nuclear
envelope precursor vesicles (i.e. vesicles that must fuse for completion of envelope assembly)
exhibit a highly unusual lipid composition -- one strikingly enriched in sterols and
phosphoinositides (Byrne et al., 2007; Garnier-Lhomme et al., 2009).
Other possibilities for why Sac1 localizes to the ER include compartment-specific
involvements for Sac1 in integration of nutrient/growth factor status with activity of membrane
trafficking through the late stages of the Golgi complex. Evidence to support such integrator
roles for Sac1 has been obtained from both the yeast and mammalian systems, and the principle
is based on differential control of the ER-Golgi-ER cycling itinerary of the Sac1 phosphatase
(Fig. 7). When yeast are cultured in nutrient-replete conditions, Sac1 is retained in the ER
where it stimulates Dpm activity in ER oligosaccharide biosynthesis (Faulhammer et al.,
2005). Efficient glycosylation of proteins is a critical component of ER quality control
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mechanisms that survey cargo incorporation into the secretory pathway (Hebert et al.,
2005;Meusser et al., 2005). Upon glucose starvation, Sac1 redistributes from the yeast ER to
the Golgi system where it is suggested to depress Golgi secretory activity by depleting Golgi
membrane PtdIns-4-P pools. In this manner, Sac1 is proposed to function as a pro-secretory
molecule when growth conditions are favorable, and as a brake when conditions are poor (Fig.
7;Faulhammer et al., 2005;Blagoveshchenskaya et al., 2008;Mayinger, 2009).
Analogous Sac1-mediated mechanisms for coupling membrane trafficking to growth factor
status also operate in mammalian cells. In this case, homo-oligomerization of Sac1 via its
leucine zipper motif must occur in a regulated manner to support timely COPII-mediated exit
of the phosphatase from the ER, and the complexes must be disassembled on demand in the
Golgi complex to promote timely COP1-mediated retrieval of the phosphatase back to the ER
(Fig. 7; Blagoveshchenskaya et al., 2008;Mayinger, 2009). The p38 mitogen-activated protein
kinase and extracellular signal-regulated kinases 1/2 regulate these events
(Blagoveshchenskaya et al., 2008).
How physiologically significant is the complex Sac1 trafficking itinerary in yeast and
mammals? As the bulk of the experiments that describe the linkage between Sac1 trafficking
and nutrient/mitogen signaling report correlative relationships, this remains an open question.
In support of views that assign high physiological significance to Sac1 traffic control are
demonstrations that yeast Sac1 expression cannot rescue Sac1 deficiencies mammalian cells
(Liu et al., 2008) -- presumably because yeast Sac1 is not outfitted to heed the various mitogenic
signals that normally control the dynamic cycling of mammalian Sac1 between ER and Golgi.
In opposition, tethering of the Sac1 catalytic domain to an ER-localized integral membrane
protein Sec61 generates an ER-localized chimera whose expression is sufficient to fully
complement all known phenotypes associated with Sac1 loss-of-function in yeast (Li et al.,
2002). Presumably, this chimera is uncoupled from the principle regulatory mechanisms that
couple yeast nutrient sensing to Sac1 trafficking. Moreover, expression of mammalian Sac1
in yeast, a protein also expected to be indifferent to the mechanisms controlling the yeast Sac1
trafficking itinerary, demonstrates it to be an effective surrogate for endogenous Sac1 (Liu et
al., 2008). One possibility for reconciling these various data is that yeast might be less sensitive
to subversion of dynamic Sac1 trafficking than are mammalian cells. Another possibility is
that normal laboratory conditions are inappropriate contexts in which to examine this question.
Nevertheless, the concept of Sac1 as integrator of nutrient/mitogen-sensing with membrane
trafficking is an enticing one that will enjoy its share of future experimental scrutiny. While,
to our knowledge, there is as yet no direct linkage between Sac1 dysfunction and disease,
establishment of such a linkage will drive further interest in this under-investigated
phosphoinositide phosphatase. In that regard, work in Drosophila demonstrates that Sac1
hypomorphism results in embryonic lethality associated with defects in dorsal closure of the
mutant embryo and deranged activation of the Jun N-terminal kinase MAPK signaling cascade
(Wei et al., 2003).
Yeast and Mammalian Fig4 Phosphatases
Another important member of the SAC-domain phosphatase family is Fig4 (Factor induced
gene; Fig. 5). First identified in yeast through a large-scale enhancer trap screen designed to
identify genes whose expression is regulated by mating pheromone (Erdman et al., 1998), Fig4
does not discharge essential functions in yeast. It is, however, required for normal mating
projection formation and actin polarization in response to mating pheromone (Erdman et al.,
1998). Fig4 harbors intrinsic polyphosphoinositide phosphatase activity with positional
specificity for the D-5 phosphoester bond of PtdIns-3,5-P2, is localized to the vacuolar
membrane, and insufficiencies cause defects in vacuole fission with the result that vacuoles
become enlarged and retrograde trafficking through the endosomal system is also impaired
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(Bonangelino et al., 2002;Gary et al., 2002;Michell et al., 2006;Michell and Dove, 2009).
Paradoxically, Fig4 is required for activation of the Fab1 PtdIns-3-P 5-OH kinase that produces
the PtdIns-3,5-P2 which, in turn, is degraded by Fig4 (Gary et al., 2002;Rudge et al.,
2004;Duex et al., 2006a;Duex et al., 2006b). It is for this reason that Fig4 loss-of-function
mutations evoke reduced, rather than elevated, intracellular PtdIns-3,5-P2. The physiological
rationale for such a paradoxical coupling between a phosphatase and a kinase remains obscure.
The Sac3 PtdIns-3,5-P2 5-phosphatase is the mammalian ortholog of yeast Fig4 (Fig. 5), and
defects in this enzyme are associated with Charcot–Marie–Tooth peripheral neuropathies
(CMT) that affect motor and sensory nerves and cause progressive distal muscle weakness and
atrophy (Quattrone et al., 1996;Berger et al., 2006;Nicot and Laporte, 2008). Haplo-
insufficiencies for the human SAC3 gene are also associated with autosomal recessive CMT4J
neuropathies (Chow et al., 2007). Insertional inactivation of murine SAC3 results in the “pale
tremor mouse” syndrome characterized by degeneration of the central nervous system,
peripheral neurophathy, and diluted pigmentation. Fibroblasts derived from pale tremor mice
exhibit enlarged late endosomal and lysosomal compartments, and reduced levels of
PtdIns-3,5-P2 (Chow et al., 2007). Thus, the paradoxical functional relationship between a
Fig4 phosphoinositide phosphatase and a Fab1 phosphoinositide kinase is preserved in the
cognate mammalian enzymes.
Phosphoinositide 5-Phosphate Phosphatases
Enzymes of the phosphoinositide 5-phosphatase family dephosphorylate the D-5 phosphoester
linkage of PtdIns-3,5-P2, PtdIns-4,5-P2 and PtdIns-3,4,5-P3 -- generating PtdIns-3-P, PtdIns-4-
P, and PtdIns-3,4-P2, respectively. This enzyme family consists of ten mammalian and four
yeast members whose activities intersect with a variety of cellular events such as synaptic
vesicle recycling, hematopoietic cell proliferation, insulin signaling, and actin organization
(Astle et al., 2006; Ooms et al., 2009). A typical feature of this enzyme family is a ca. 300
residue central catalytic polyphosphate 5-phosphatase domain highlighted by two signature
motifs -- WXGDXN(F/Y)R and P(A/S)W(C/T)DRIL -- spaced some 60–75 residues apart
(Majerus et al., 1999). Crystallographic studies reveal these 5-phosphatases belong to the AP
endonuclease family highlighted by a catalytic mechanism which employs a His/Asp active
site pair (Dyson et al., 2005).
Oculocerebrorenal Lowe Syndrome (OCRL) Phosphatase
OCRL is a devastating human X-linked developmental disorder that occurs in approximately
1 in 200,000 births, and is characterized by a variety of ocular, neurological, cognitive, renal,
and musculoskeletal abnormalities (Lowe et al., 1952; Leahey et al., 1993; Hoopes et al.,
2005). Ocular syndromes include bilateral congenital cataracts, glaucoma, and
microphthalmos. Neonatal hypotonia, mental retardation, araflexia, and behavioral
abnormalities represent neurological manifestations. Renal defects include kidney absorbtion
insufficiencies associated with Fanconi syndrome of kidney proximal tubules and type 2 Dent
disease. The kidney malabsorbtion phenotypes contribute to the musculoskeletal defects that
are manifested in joint hypermobility and in fracture-prone bones.
The molecular etiology of Lowe’s syndrome is loss-of-function for the OCRL1 inositol
polyphosphate 5-phosphatase (Attree et al., 1992; Leahey et al., 1993). OCRL1 exhibits three
conserved domains -- the central inositol polyphosphate 5-phosphatase domain, an ASH
domain, and a C-terminal catalytically inactive Rho guanosine triphosphatase-activating
protein (GAP)-like domain (Fig. 5; Lowe, 2005; Erdmann et al., 2007). OCRL1 shares 51%
primary sequence identity with INPP5B, the only other inositol polyphosphate 5-phosphatase
with a GAP-like domain in humans and mice (Jefferson and Majerus, 1995; Speed et al.,
1995; Matzaris et al., 1998). Both OCRL1 and INPP5B hydrolyze PdIns-4,5-P2 and
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PtdIns-3,4,5-P3, as well as the soluble inositol polyphosphates Ins-1,4,5-P3 and Ins-1,3,4,5-
P4, but with distinct substrate preferences. While PdIns-4,5-P2 is preferred to PtdIns-3,4,5-
P3 by both OCRL1 and INPP5B, the latter does not discriminate between molecular species
of these phosphoinositides and does not dephosphorylate PtdIns-3,5-P2 (Zhang et al., 1995;
Zhang et al., 1998; Schmid et al., 2004). Available evidence suggests INPP5B systematically
dephosphorylates PtdIns-3,4,5-P3 to PtdIns-3-P, a key phosphoinositide required for endosome
homeostasis (Shin et al., 2005). Some measure of functional redundancy likely exists between
OCRL1 and INPP5B in mice. Combinatorial ablation of OCRL1 and INPP5B structural genes
results in embryonic lethality, while OCRL1 nullizygosity does not result in murine Lowe
syndrome disease (Janne et al., 1998). Lower eukaryotes (flies, worms and amoeba) express
only one of those two proteins, and no GAP-like domain-containing 5-phosphatases are
expressed in yeast (Lowe, 2005).
The OCRL1 protein localizes to the trans-Golgi network (TGN) and early endosomes (Fig. 6;
Olivos-Glander et al., 1995;Ungewickell et al., 2004;Choudhury et al., 2005;Faucherre et
al., 2005). OCRL1 also interacts with the small GTPase Rac and the TGN/endosomal adaptor
protein APPL1 via its Rho-GAP domain. These interactions target the enzyme to the TGN/
endosomal system (Faucherre et al., 2003;Erdmann et al., 2007;McCrea et al., 2008). The
presence of OCRL1 in clathrin-decorated budding profiles at the TGN, and as cargo in clathrin-
coated vesicles (CCV) shuttling between the TGN and endosomes, suggests this phosphatase
plays a role in vesicular transport between these compartments (Ungewickell et al.,
2004;Choudhury et al., 2005). The redistribution of cargo that cycles between TGN and
endosomes (e.g. TGN46) to early endosomal compartments (accompanied by endosome
enlargement) upon siRNA-mediated OCRL1 depletion supports this view. Thus, retrograde
trafficking from endosomes to the TGN is compromised by OCRL1-insufficiencies, and the
5-phosphatase domain is essential for OCRL1-mediated control of this trafficking step
(Choudhury et al., 2005). Morever, mutations that reside in non-catalytic domains of OCRL1
(i.e. the RhoGAP-like and ASH domains) all result in mislocalization of the enzyme by
compromising its ability to bind APPL1 (Erdmann et al., 2007;McCrea et al., 2008).
The mechanism for how OCRL1 controls clathrin-mediated membrane trafficking through the
TGN/endosome system involves regulation of PtdIns-4-P and/or PtdIns-4,5-P2 levels.
PtdIns-4-P, together with ARF GTPases, facilitates membrane recruitment of effector proteins
(e.g. clathrin adaptors AP1, an AP1/clathrin interacting protein epsinR, and lipid-binding
proteins such as oxysterol-binding proteins) that regulate the biogenesis and dynamics of the
TGN/endosomal system (Kalthoff et al., 2002; Li et al, 2002; Mills et al., 2003; Wang et al.,
2003; Godi et al., 2004). Loss of OCRL1-mediated degradation of PtdIns-4,5-P2 to PtdIns-4-
P in TGN/endosomes might upset balanced recruitment of these effector proteins to membranes
due to PtdIns-4-P insufficiency. Alternatively, given PtdIns-4,5-P2 plays an essential role in
clathrin-mediated endocytosis, by facilitating recruitment of clathrin accessory proteins to the
plasma membrane, OCRL1 inactivation may provoke PtdIns-4,5-P2 derangements which
influence the TGN/endosomal system indirectly (Wang et al., 2003; Legendre-Guillemin et
al., 2004).
OCRL1 is suggested to regulate actin dynamics on the basis that actin organization is defective
in Lowe syndrome fibroblasts (Suchy and Nussbaum, 2002). This effect likely reflects an
indirect relationship between ORCL1 and actin dynamics, however. Even subtle derangements
in phosphoinositide levels, particularly those of PtdIns-4,5-P2, can upset the delicate
homeostatic balance between actin and actin binding proteins -- as occurs in yeast mutants
deficient for the Sac1 phosphoinositide phosphatase (Novick et al., 1989; Cleves et al., 1989;
Cleves et al., 1991; Whitters et al., 1993). Abnormal Ca2+ signaling may also confuse actin
dynamics (Suchy et al., 2009).
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The synaptojanins are dual function Sac-domain phosphatases also evolutionarily conserved
from yeast to humans. Synaptojanin 1 was discovered by Pietro De Camilli and colleagues as
a nerve terminal protein that functions in synaptic vesicle endocytosis and recycling
(McPherson et al., 1994a; McPherson et al., 1994b). This protein is characterized by an N-
terminal Sac1-like polyphosphate phosphatase domain which converts PtdIns-3-P, PtdIns-4-
P, PtdIns-5-P and PtdIns-3,5-P2 to PtdIns, and a central inositol polyphosphate 5-phosphatase
domain that hydrolyze phosphoinositides at the D-5 position of the inositol ring (Fig. 5;
McPherson et al., 1996; Haffner et al., 1997). The synaptojanin 1 C-terminus is subject to
modification by alternative splicing programs in adult vs developing neurons, and exhibits a
proline-rich region which mediates of synaptojanin 1 interaction with the Src homology 3
(SH3) domains of Grb2 (McPherson et al., 1994a; McPherson et al., 1994b). Grb2 is a 25-kDa
adaptor protein with two SH3 domains that flank a Src homology 2 (SH2) domain, and this
adaptor is a regulatory component of the synaptic vesicle cycle and neurotransmitter release.
Candidate Grb2 effectors include dynamin (a GTPase required for synaptic vesicle
endocytosis) and synapsin I -- a synaptic vesicle-associated protein that mediates interaction
of synaptic vesicles with the presynaptic cytomatrix (McPherson et al., 1994a).
The synaptojanin 2 catalytic domain is closely related to that of synaptojanin 1 at the primary
sequence level, is also a phosphoinositide 5-phosphatase, and displays a broader tissue
distribution than synaptojanin 1. The two synaptojanins exhibit unrelated C-terminal regions,
and this property manifests itself in the differential protein-protein interaction spectra of these
enzymes (Nemoto et al., 1997; Khvotchev and Südhof, 1998). Whereas synaptojanin 2 binds
the SH3 domain containing protein, Grb2, synaptojanin 1 not only binds Grb2, but also
amphiphysin and members of SH3p4/8/13 protein family via its C-terminal proline-rich
domain (Nemoto et al., 1997). The two synaptojanin isoforms are directed to distinct
subcellular locations as a result of their unique sets of protein-protein interactions (Nemoto et
al., 1997).
Synaptojanins 1 and 2 exhibit distinct biological functions. Synaptojanin 1 nullizygous mice
survive to term but die shortly after birth. The neonates present neurological defects and
accumulate clathrin-coated vesicles at nerve endings, a consequence of impaired turnover of
a plasma membrane PtdIns-4,5-P2 pool whose persistence interferes with disassembly of
clathrin coats and results in defective synaptic transmission (Cremona et al., 1999; Kim et
al., 2002). This regulatory function may have other interesting neurological manifestations.
The synaptojanin 1 structural gene resides in a genomic region present in trisomic arrangement
in Ts65Dn mice, a model for Down’s syndrome, and PtdIns-4,5-P2 homeostasis is altered in
brains of these mice (Voronov et al., 2008). The neurological and PtdIns-4,5-P2 homeostatic
defects that characterize Ts65Dn mice are corrected by restoring synaptojanin 1 structural gene
to disomy, and the trisomy of the synaptojanin 1 structural gene alone is sufficient to
recapitulate Down’s syndrome in mice. Given the human synaptojanin 1 structural gene is
located on the trisomic chromosome 21 of human Down’s syndrome patients, it is an attractive
proposition that increased synaptojanin 1 activity is directly associated with the brain
dysfunction and cognitive defects of this disease (Voronov et al., 2008).
Synaptojanin 2 functions in non-neuronal cells by regulating an early step in the clathrin-
mediated endocytic pathway (Hill et al., 2001; Rusk et al., 2003). Synaptojanin 2 specifically
binds the GTP-bound form of the small GTPase Rac1, and overexpression of a membrane-
targeted version of synaptojanin 2 inhibits endocytosis of epidermal growth factor (EGF) and
transferrin receptors (Malecz et al., 2000). Moreover, siRNA experiments demonstrate
depletion of synaptojanin 2 (but not synaptojanin 1) compromises clathrin-mediated
internalization of EGF receptor and antagonizes formation of clathrin-coated pits and CCVs
in lung carcinoma cells (Rusk et al., 2003). The synaptojanin execution point at late stages of
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the secretory pathway, and in endocytosis, is conserved. Dysfunction of the yeast synaptojanin
homolog Inp53/Sjl3 comprises protein transport from the TGN to endosomes (Ha et al.,
2003).
SHIP Polyphosphate 5-Phosphatases
SHIP1, the prototype for the SH2 domain-containing inositol polyphosphate-5-phosphatases,
was discovered in murine hematopoietic cells as a component of a Grb2- and Shc-containing
complex (Damen et al., 1996; Kavanaugh et al., 1996; Lioubin et al., 1996). SHIP1 is a 145-
KDa protein with an N-terminal SH2 domain, a central catalytic 5-phosphatase domain that
contains the two highly conserved signatures of inositol polyphosphate 5-phosphatases, a C-
terminal proline-rich region with consensus sites for SH3 domain interactions, and two
potential phosphotyrosine binding (PTB) domain-binding sites (NPXY) at the C-terminus (Fig.
5; Damen et al., 1996; Backers et al., 2003). Both humans and rodents also express a related
142-KDa protein (SHIP2) that is widely expressed in different tissues in human with
particularly high levels in heart, skeletal muscle and placenta (Pesesse et al., 1997; Pesesse et
al., 1998; Ishihara et al., 1999). The domain structure of SHIP2 is similar to that of SHIP1 with
the exception that SHIP2 harbors a unique C-terminal sterile alpha motif (SAM) domain which
mediates homotypic SAM-domain protein interactions (Fig. 5). Such interactions modulate
EphrinA2 receptor internalization and degradation, a process that may also dampen growth
factor signaling (Zhuang et al., 2007). SHIP1 and 2 utilize both PtdIns-3,4,5-P3 and Ins-1,3,4,5-
P4 as substrates and dephosphorylate these compounds at the D-5 position of the inositol ring
(Damen et al., 1996; Pesesse et al., 1998). Kinetic studies report the substrate hierarchy for
SHIP2 as Ins-1,2,3,4,5-P5 > Ins-1,3,4,5-P4 > PtdIns-3,4,5-P3. PtdIns-3,5-P2, and the soluble
Ins-1,4,5,6-P4, and Ins-2,4,5,6-P4, are utilized as substrates with approximately the same
efficiency as PtdIns-3,4,5-P3 (Chi et al., 2004).
With regard to biological functions, SHIP1 is involved in regulation of the immune response
and in survival of myeloid cells while SHIP2 is involved in downregulation of insulin signaling
(Huber et al., 1999; Liu et al., 1999; Clement et al., 2001; Sasaoka et al., 2004). Upon growth
factor stimulation, SHIP1 translocates from the cytosol to the plasma membrane, and this
redistribution is associated with downregulation of signaling via the MAP kinase pathway
(Rohrschneider et al., 2000).Similarly, upon insulin stimulation, SHIP2 is redistributed to the
plasma membrane with consequent depression of PI3K-dependent insulin signaling resulting
from SHIP2-mediated dephosphorylation of PtdIns-3,4,5-P3 to PtdIns-3,4-P2 (Sasaoka et al.,
2004). These data indicate the SHIP1 and SHIP2 enzymes primarily survey agonist-stimulated
PtdIns-3,4,5-P3 pools. This is in contrast to PTEN, which accesses both signaling and basal
pools of PtdIns-3,4,5-P3 and remains active after long-term stimulation (Stambolic et al.,
1998; Liu et al., 1999; Leslie and Downes, 2002; Blero et al., 2005).
Summary
The evolution of inositol as a compact, yet versatile, signaling scaffold, one subject to position-
specific phosphorylation, has allowed eukaryotes to multiplex the channels of signaling that
pass through this simple six-carbon chemical backbone. The intricacies of inositol signaling
are accompanied by a correspondingly complex enzymology that governs phosphoinositide
synthesis and degradation in a spatially and temporally controlled manner. Degradation of
phosphoinositides by phosphatases that do not produce soluble second messenger products is
a major pathway for phosphoinositide homeostatic control, as evidenced not only by the
number of phosphatases dedicated to phosphoinositide catabolism, but also by the direct
linkage of phosphoinositide phosphatase deficiencies to an array of human diseases. From the
basic science perspective, the domain arrangements of some phosphoinositide phosphatases
are intriguing. For example, why are Sac-domains often physically appended to
phosphoinositide 5-phosphate phosphatase catalytic domains? Is this arrangement analogous
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to the interface between phosphoinositide 3-phosphate phosphatases and their catalytically-
dead subunits, or does it describe an intimate arrangement for metabolic channeling of
substrates? These curious modularities must reflect some fundamental property of these
enzymes. Although emerging evidence favors metabolic channeling models (Mani et al.,
2007), the nature of that property remains uncertain.
Do phosphoinositide phosphatases play unappreciated roles in promoting signaling? These
enzymes degrade phosphoinositides species to other phosphoinositide products that have their
own signaling potential after all. How are the phosphatase reactions channeled to prevent
precocious activation of signaling? How determining is the mode of phosphoinositide
production in terms of signaling outcome (e.g. PtdIns-4-P via action of a PtdIns 4-OH kinase
as opposed to degradation of PtdIns-4,5-P2 by a phosphoinositide 5-phosphate phosphatases)?
These remain questions for future study.
From the perspective of human disease, the relevance of phosphoinositide phosphatases is
established. These disease connections, when coupled with a thorough mechanistic
understanding of how phosphoinositide phosphatases function in cells, will further reinforce
interest in these enzymes as attractive druggable targets. When the pharmacological
encyclopedia of treatment for human diseases is written, we expect that phosphoinositide
phosphatases will occupy a significant place in the roster of targets.
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Phosphoinositides are phosphorylated derivatives of PtdIns. The chemical structures of PtdIns
and Phosphoinositides are shown highlighting the inositol headgroup, glycerol backbone and
two fatty acyl chains. The inositol headgroup can be combinatorially phosphorylated at the
D-3OH, -4OH, -5OH positions of the inositol ring as indicated in red.
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Phosphoinositide metabolism in the yeast Saccharomyces cerevisiae. The execution points of
the yeast PtdIns kinases and phosphoinositide phosphatases that regulate the synthesis and
turnover of phosphoinositides, respectively, are identified.
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Phosphoinositide metabolism in mammalian cells. The execution points of the mammalian
PtdIns kinases and phosphoinositide phosphatases that regulate the synthesis and turnover of
Phosphoinositides, respectively, are identified.
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Catalytic mechanisms of phosphoinositide phosphatases. (A) The CX5R(T/S)
phosphoinositide phosphatases of the PTP superfamily. These enzymes catalyze a double-
displacement reaction where the leaving group alcohol is displaced by an active-site
nucleophile. The resulting phospho-enzyme intermediate is resolved by transfer of the PO3
group to an acceptor water molecule. An aspartic acid subsequently donates a proton to the
leaving-group oxygen to regenerate an uncharged hydroxy group at the position from which
the PO3 group was displaced (Guan and Dixon, 1991; Fauman and Saper, 1996; Hughes et
al., 2000a). (B) The inositol polyphosphate 5’-phosphatases of the AP endonuclease
superfamily. These enzymes catalyze a displacement reaction where the leaving group alcohol
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is displaced by an actived water molecule as nucleophile. An invariant Asp residue, held in
properly position by H-bonding with a conserved Asn, activates the nucleophilic water (1). A
His/Asp pair cooperates with an invariant Asn to position the target phosphate bond for
hydrolysis. Mg2+ is thought to stabilize a transition state in the reaction. There is no
phosphoenzyme intermediate in this catalytic mechanism as the PO3 group is transferred
directly to the nucleophilic water molecule (2). Either water, or some other functional group
of the enzyme (both possibilities generically designated as XH*; 3), donates a proton to the
leaving-group oxygen to regenerate an uncharged hydroxyl group at the position from which
the PO3 group was displaced.
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Domain organization of phosphoinositide phosphatases. The domain structures of PTEN,
MTM1, Sac1, Fig4, OCRL1, INPP5B, Synaptojanin 1,2, and SHIP1,2 are illustrated. Relevant
functional domains and motifs are indicated.
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Phosphoinositide phosphatases and regulation of membrane trafficking. The phosphoinositide
4-phosphatase Sac1 is localized primarily in ER and Golgi membranes. OCRL1 (yellow) is
localized to the Golgi/endosomal system and is a cargo of the clathrin-coated vesicles (CCVs)
responsible for bidirectional membrane trafficking between TGN and endosomes. In the
neuronal presynaptic plasma membrane, a PtdIns- 4,5-P2 pool is accessed by synaptojanin 1
during CCV uncoating. In non-neuronal cells, synaptojanin 2 (maroon) functions at an early
stage of clathrin-mediated endocytosis. MTM1 (pink) regulates endocytic traffic and PTEN
(red) degrades a PtdIns-3,4,5-P3 pool involved in membrane trafficking events associated with
phagocytosis. Abbreviations: CCP, clathrin-coated pit; CCV, clathrin-coated vesicle; EE, early
endosome; ER, endoplasmic reticulum; Ly, lysosome; MVB/LE, multivesicular body/late
endosome; PGC, post-Golgi carrier; SV, secretory vesicle; TGN, trans-Golgi network.
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Dynamic regulation of Sac1 localization in yeast and mammals. When yeast cells are in
exponential growth, the ER dolicholphosphate mannose synthase Dpm1p interacts with yeast
Sac1 (ySac1) via their respective trans-membrane domains. This interaction restricts Sac1 to
the ER, results in elevated Golgi PtdIns-4-P, and promotes robust secretory activity (A). Upon
nutrient limitation, the ySac1 interaction with Dpm1p is broken and ySac1 escapes to Golgi
membranes. Increased Golgi ySac1 reduces PtdIns-4-P levels and, subsequently, secretory
activity (B). In mammalian cells, growth factor signaling promotes retrograde transport of Sac1
from Golgi membranes to the ER via an ARF- and COPI-dependent pathway. Consequent
elevation of Golgi PtdIns-4-P promotes optimal secretion (C). In quiescent cells, Sac1
oligomerizes and translocates to the Golgi via a COPII-mediated pathway. Increased Golgi
Sac1 reduces PtdIn-4-P pools and downregulates secretory activity (D).
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